Vividion Therapeutics logo

Vividion Therapeutics Funding & Investors

Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. The company’s cutting-edge platform was spun out of the labs of Vividion’s scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA.

vividion.com

Total Amount Raised: $371,504,608

Vividion Therapeutics Funding Rounds

  • Series C

    $135,000,000

    Series C Investors

    Boxer Capital
    Logos Capital
    Arch Venture Partners
    Biotechnology Value Fund
    Ra Capital Management
    Versant Ventures
    Casdin Capital
    Mubadala Capital Ventures
    Driehaus Capital Management
    Nextech Invest
    Surveyor Capital
    T. Rowe Price
    Acuta Capital Partners
    SoftBank Vision Fund
    Avoro Capital Advisors
    Woodline Partners
  • Series B

    $82,000,000

    Series B Investors

    Nextech Invest
    Casdin Capital
    Trinitas Capital
    Altitude Life Science Ventures
    Mubadala Capital Ventures
    Alexandria
    Mirae Asset
    Biotechnology Value Fund
    Versant Ventures
    Cardinal Partners
    Arch Venture Partners
    Celgene
  • Corporate Round

    $101,000,000

    Corporate Round Investors

    Celgene
  • Series A

    $50,000,000

    Series A Investors

    Arch Venture Partners
    Versant Ventures
    Cardinal Partners
  • Series A

    $3,504,616

    Series A Investors

    Cardinal Partners
Funding info provided by Diffbot.